The September issue of the journal “Archives of the Balkan Medical Union“ is ready and has lots of interesting subjects for its readers. Diffuse large B‑cell lymphoma is a common form of non‑Hodgkin’s malignant lymphomas, occurring at all ages.
Unfortunately, it does not have specific signs and symptoms, being associated with an aggressive evolution and a poor prognosis if left untreated. The study of Birceanu Corobea et al (Bucharest, Romania), “The clinical importance of PD‑L1 and PD‑1 expression in diffuse large B cell lymphoma“, investigated the role of PD‑1 (programmed cell death‑1) and PD‑L1 (programmed death‑ligand 1) in diffuse large B cell lymphoma. Their results suggest that PD‑1 and PD‑L1 could be potential biomarkers for targeted treatment in some patients diagnosed with diffuse large B‑cell lymphoma.
Malignant lymphomas of the head and neck may raise therapeutic difficulties. In their minireview “Therapeutic methods used in the treatment of malignant lymphomas of the head and neck“, Tusaliu et colleagues, from the University of Medicine and Pharmacy “Carol Davila“, Bucharest, Romania, evaluated the therapeutic methods used in malignant lymphoma, such as conventional chemotherapy, radiotherapy, surgical treatment, salvage treatment, interferon treatment, monoclonal antibody treatment, medullar transplantation, and peptide treatment.